NRx Pharmaceuticals (NASDAQ:NRXP) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $31.00 price objective on the stock.

A number of other research analysts also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a report on Monday, November 25th. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st. Finally, Ascendiant Capital Markets raised their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd.

NRx Pharmaceuticals Price Performance

NASDAQ:NRXP opened at $2.20 on Tuesday. The firm has a 50-day moving average of $1.31 and a two-hundred day moving average of $1.76. The stock has a market cap of $26.61 million, a P/E ratio of -1.03 and a beta of 1.25. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $7.33.

Insider Buying and Selling

In other news, Chairman Jonathan C. Javitt purchased 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were acquired at an average cost of $1.17 per share, with a total value of $46,800.00. Following the transaction, the chairman now owns 84,634 shares in the company, valued at approximately $99,021.78. The trade was a 89.62 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 19.00% of the company’s stock.

Hedge Funds Weigh In On NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Anson Funds Management LP purchased a new position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned about 1.33% of NRx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.